The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
NCCN multiple myeloma practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 1.2003.Rockledge, PA: National Comprehensive Cancer Network; 2003.
2.
BarlogieB., VelasquezW.S., AlexanianR.Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.J Clin Oncol.1989; 7: 1514–7.
3.
BarlogieB., JagannathS., DesikanK.R.Total therapy with tandem transplants for newly diagnosed multiple myeloma.Blood.1999; 93: 55–65.
4.
BarlogieB., VesholeD., JagannathS.Salvage therapy for multiple myeloma: The University of Arkansas experience.Mayo Clin Proc.1994; 69: 787–95.
5.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
6.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
7.
NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 2.2003. Rockledge, PA: National Comprehensive Cancer Network; 2003.
8.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34: 1857–64.
13.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors.Curr Opin Hematol.1999; 6: 145–51.
14.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care.Eur J Cancer.2000; 36(suppl 1): S15–S21.
15.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.Gynecol Oncol.1993; 50: 147–58.
HigaG.M., GockermanJ.P., HuntA.L.The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.Cancer.1991; 68: 1691–3.
18.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49: 1796–9.
19.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–405.
20.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–74.
21.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 494–504.
22.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
23.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–89.
24.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic agents. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 483–493.
